VFA
SNDX icon

Values First Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Values First Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,546
Closed -$29.8K – 286
2024
Q3 		$29.8K Buy
+1,546
New +$31.9K 0.02% 257

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Values First Advisors's SNDX Position: Q4 2024 in Review

Values First Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q4 2024, closing a stake of 1,546 shares — an estimated $29.8K sold.

Values First Advisors first reported a position in SNDX in Q3 2024 and held it in 1 quarter. The position peaked at $29.8K in Q3 2024. 215 funds tracked by Wall St. Rank hold SNDX as of Q4 2024.

  • Values First Advisors reported no remaining Syndax Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Values First Advisors sold 1,546 Syndax Pharmaceuticals shares in Q4 2024, an estimated $29.8K.
  • Values First Advisors first reported a position in Syndax Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Values First Advisors's Syndax Pharmaceuticals position peaked at $29.8K in Q3 2024.
  • 215 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2024.

Based on Values First Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.